2019 Coding Guide

Diagnosis and Billing Codes

**DISCLAIMER:**
The following publicly available information is presented for illustrative purposes only and is not intended to provide coding, reimbursement, treatment, or legal advice. It is not intended to guarantee, increase or maximize reimbursement by any payer.

Laws, regulations and policies concerning reimbursement are complex and are updated frequently. Individual coding decisions should be based upon diagnosis and treatment of individual patients. BTG does not warrant, promise, guarantee, or make any statement that the codes supplied in this guide are appropriate or that the use of this information will result in coverage or payment for treatment using CroFab® or that any payment received will cover providers’ costs. BTG is not responsible for any action providers take in billing for, or, appealing CroFab® claims. Hospitals and physicians are responsible for compliance with Medicare and other payer rules and requirements and for the information submitted with all claims and appeals. Before any claims or appeals are submitted, hospitals and physicians should review official payer instructions and requirements, should confirm the accuracy of their coding or billing practices with these payers, and should use independent judgment when selecting codes that most appropriately describe the services or supplies furnished to a patient. It is the provider’s responsibility to determine and document that the services provided are medically necessary and that the site of service is appropriate.

While we have made an effort to be current as of the issue date of this document, the information may not be current when you view it. Providers are encouraged to contact third-party payers for specific information on their coverage, coding and payment policies. Please consult with your legal counsel or reimbursement specialists.

### Potentially Applicable Diagnosis and Procedure Codes

#### ICD-10 Diagnosis Codes

<table>
<thead>
<tr>
<th>ICD-10-CM Diagnosis Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>T63.011A</td>
<td>Toxic effect of rattlesnake venom, accidental (unintentional), initial encounter</td>
</tr>
<tr>
<td>T63.061A</td>
<td>Toxic effect of venom of other North and South American snake, accidental (unintentional), initial encounter [use for copperhead bite]</td>
</tr>
<tr>
<td>T63.091A</td>
<td>Toxic effect of venom of other snake, accidental (unintentional), initial encounter [use for water moccasin bite]</td>
</tr>
</tbody>
</table>

**6th digit options**
- 2 (intentional self-harm),
- 3 (assault),
- 4 (undetermined)

**7th digit options**
Qualifier could also be D - subsequent encounter or S - sequela

**ICD-10=International Classification of Diseases, Tenth Revision.**
**ICD-10 PC=International Classification of Diseases, Tenth Revision, Procedure Coding System.**
**HCPCS=Healthcare Common Procedure Coding System.**
**NDC=National Drug Code.**

#### ICD-10 Procedure Code

<table>
<thead>
<tr>
<th>ICD-10-PCS Procedure Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>3E0334Z</td>
<td>Introduction of Serum, Toxoid and Vaccine into Peripheral Vein, Perc Approach</td>
</tr>
</tbody>
</table>

Reimbursement Questions and Support

CroFab@btgplc.com
1-844-293-0007
Option 4

Please see accompanying full Prescribing Information. Please see Indication and Important Safety Information.
# 2019 Coding Guide

## Diagnosis and Billing Codes

### Potentially Applicable MS-DRG and Other Codes

<table>
<thead>
<tr>
<th>MS-DRG Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>917</td>
<td>Poisoning and toxic effects of drugs with major complications/co-morbidity</td>
</tr>
<tr>
<td>918</td>
<td>Poisoning and toxic effects of drugs without major complications/co-morbidity</td>
</tr>
</tbody>
</table>

CroFab® reimbursement is part of the diagnosis-related group (MS-DRG) payment weight in the Medicare Part A Inpatient Prospective Payment System payment equation. Medicaid reimbursement (FFS and Managed Care) will vary by state. For other payors, specific benefit coverage and reimbursement varies by provider contract.

### HCPCS Code - Commercial Payers

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0840</td>
<td>Crotalidae Polyvalent Immune Fab (Ovine), 1 vial</td>
</tr>
</tbody>
</table>

Commercial payers may request the product-specific HCPCS code for reimbursement of CroFab® in the outpatient setting. Please consult the appropriate payer for specific coverage and reimbursement requirements.

### Revenue Codes

<table>
<thead>
<tr>
<th>Revenue Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>0450</td>
<td>Emergency department visit</td>
</tr>
<tr>
<td>0636</td>
<td>Drugs requiring detailed coding</td>
</tr>
</tbody>
</table>

### NDC

<table>
<thead>
<tr>
<th>NDC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>50633-110-12</td>
<td>Use NDC#: 50633-0110-12 when 11 digits are required</td>
</tr>
</tbody>
</table>

CroFab® is supplied as a carton that contains 2 vials of product (diluent not included). Each vial of CroFab® contains up to 1 gram of lyophilized total protein and not less than the indicated number of mouse LD50 (50% lethal dose) neutralizing units.

### Reimbursement Questions and Support

CroFab@btgplc.com
1-844-293-0007 Option 4

Please see accompanying full Prescribing Information. Please see Indication and Important Safety Information.
**Indication**
CroFab® Crotalidae Polyvalent Immune Fab (Ovine) is a sheep-derived antivenin indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins.

**Important Safety Information**

**Contraindications**
Do not administer CroFab® to patients with a known history of hypersensitivity to any of its components, or to papaya or papain unless the benefits outweigh the risks and appropriate management for anaphylactic reactions is readily available.

**Warnings and Precautions**

**Coagulopathy:** In clinical trials, recurrent coagulopathy (the return of a coagulation abnormality after it has been successfully treated with antivenin), characterized by decreased fibrinogen, decreased platelets, and elevated prothrombin time, occurred in approximately half of the patients studied; one patient required re-hospitalization and additional antivenin administration. Recurrent coagulopathy may persist for 1 to 2 weeks or more. Patients who experience coagulopathy due to snakebite should be monitored for recurrent coagulopathy for up to 1 week or longer. During this period, the physician should carefully assess the need for re-treatment with CroFab® and use of any type of anticoagulant or anti-platelet drug.

**Hypersensitivity Reactions:** Severe hypersensitivity reactions may occur with CroFab®. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CroFab®. Follow-up all patients for signs and symptoms of delayed allergic reactions or serum sickness (e.g., rash, fever, myalgia, arthralgia).

**Adverse Reactions**
The most common adverse reactions (incidence ≥5% of subjects) reported in the clinical studies were urticaria, rash, nausea, pruritus and back pain. Adverse reactions involving the skin and appendages (primarily rash, urticaria, and pruritus) were reported in 12 of the 42 patients. Two patients had a severe allergic reaction (severe hives and a severe rash and pruritus) following treatment and one patient discontinued CroFab® due to an allergic reaction. Recurrent coagulopathy due to envenomation and requiring additional treatment may occur.

**Reimbursement Questions and Support**
CroFab@btgplc.com
1-844-293-0007
Option 4

**Reference:**
1. CroFab® prescribing information.